Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Press/Media
Datasets
Activities
Fellowships, Honors, and Prizes
Search by expertise, name or affiliation
Apixaban to Prevent Recurrence after Cryptogenic Stroke in Patients with Atrial Cardiopathy the ARCADIA Randomized Clinical Trial
ARCADIA Investigators
Neurology
Research output
:
Contribution to journal
›
Article
›
peer-review
5
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Apixaban to Prevent Recurrence after Cryptogenic Stroke in Patients with Atrial Cardiopathy the ARCADIA Randomized Clinical Trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
apixaban
100%
Stroke
49%
Randomized Controlled Trials
48%
Recurrence
41%
Atrial Fibrillation
38%
Aspirin
33%
Intracranial Hemorrhages
16%
Random Allocation
14%
Medical Futility
10%
Hemorrhage
9%
Phase III Clinical Trials
8%
Brain Natriuretic Peptide
7%
National Institutes of Health (U.S.)
7%
Secondary Prevention
7%
Lead
6%
Electrocardiography
5%
Health Care Outcome Assessment
4%
Safety
4%
Serum
3%
Therapeutics
1%